You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,022,687


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,022,687
Title: Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
Abstract:A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-.beta. type I receptor (RI), TGF-.beta. type II receptor (RII), or TGF-.beta./activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT.
Inventor(s): Letarte; Michelle (Toronto, CA), Marchuk; Douglas A. (Chapel Hill, NC), McAllister; Kimberly (Durham, NC)
Assignee: Duke University (Durham, NC)
Application Number:08/564,496
Patent Claims:1. A diagnostic method comprising

determining whether a sample of genomic DNA provided from a patient or fetus suspected of being susceptible to hereditary haemorrhagic telangiectasia (HHT) comprises a mutation in a gene encoding endoglin, said mutation being an indication that said patient or fetus is susceptible to HHT.

2. The method of claim 1, wherein said method includes the step of treating said sample of genomic DNA with a restriction enzyme selected from the group consisting of MaeIII and BbvI.

3. The method of claim 1, wherein said method includes the step of subjecting said sample to polymerase chain reaction (PCR), using a forward PCR primer complementary to a portion of the antisense strand of said gene, said portion being within (a) a first intron of said gene, or (b) the 5' untranslated region adjacent to the start codon of said gene; and a reverse PCR primer complementary to a fragment of the sense strand of said gene, said fragment being within (a) a second intron of said gene, or (b) the 3' untranslated region adjacent to the termination codon of said gene.

4. The method of claim 1, wherein said sample is obtained by amniocentesis or chorionic villi sampling.

5. A diagnostic method comprising determining whether endoglin mRNA provided from a patient or fetus comprises a mutation, the presence of the mutation indicating that the patient or fetus is genetically predisposed to developing the HHT phenotype.

6. The method of claim 5, wherein said mRNA is obtained from a tissue comprising peripheral blood.

7. The method of claim 5, wherein said mutation is detected by examining the sequence of cDNA obtained by subjecting endoglin mRNA to reverse transcription-PCR (RT-PCR).

8. The method of claim 5, further comprising

identifying a patient or fetus suspected of being genetically predisposed to developing the HHT phenotype; and

obtaining from said patient or fetus a sample of mRNA from a tissue which normally expresses a gene of the TGF-.beta. receptor complex.

9. A diagnostic method comprising determining whether a sample of genomic DNA obtained from a patient or fetus comprises a mutation in a gene encoding betaglycan, TGF-.beta. type II receptor (RII), or TGF-.beta./activin type I receptor (TSR-I), said mutation being an indication that the patient or fetus is susceptible to hereditary haemorrhagic telangiectasia.

10. The method of claim 9, comprising determining whether genomic DNA obtained from the patent or fetus includes a mutation in a gene encoding TSR-I.

11. A diagnostic method comprising determining whether betaglycan mRNA, TGF-.beta. type II receptor (RII) mRNA, or TGF-.beta./activin type I receptor (TSR-I) mRNA obtained from a patient or fetus includes a mutation, the presence of the mutation indicating that the patient or fetus is genetically predisposed to developing the HHT phenotype.

12. The method of claim 11, comprising determining whether mRNA obtained from the patent or fetus includes a mutation in a gene encoding TSR-I.

Details for Patent 6,022,687

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.